Roseway Labs Announces Plans to Launch in the EU

Roseway Labs, specialists in providing personalised medication, has announced plans to bring its services to the European Union (EU) prescribers.

Founded in 2018 in the UK by Chief Executive Officer Elizabeth Philp and Superintendent Pharmacist Miriam Martinez Callejas, Roseway’s driving passion was to provide solutions for patients with special medical needs and give prescribers access to hard-to-find medication.

Six years later, the company has done just that. Their unique offering combines compounded medication with licensed and unlicensed medication, along with supplements, diagnostic kits and stock for clinical use. No other UK pharmacy offers the same breadth of services, and they are now excited to announce plans to bring this same level of expertise and dedication to meeting patients’ needs to prescribers working in EU countries.

Customer service and integrity are at the heart of what Roseway Labs do. “We're not here to sell. We're here to solve”, Elizabeth says. “We are all about offering patients and prescribers choices. It gives people the opportunity to access solutions when regular medication hasn't dealt with their problem.”

Branching out to the EU is the next phase of growth for the company, which has been operating at the forefront of the movement towards personalised medicine in the UK. The move is an exciting prospect for Spanish-trained Miriam, who holds a Master’s Degree in Pharmacy with international experience in bio-pharmacy research, compounding and nutrition and entrepreneurial co-founder Elizabeth, who has a BSc in Chemistry and Mathematics, an MSc in Organisational Behaviour and an MBA from London Business School.

“We know people who live in the EU and come to the UK for medicine, so we're just bringing that to them”, Elizabeth says. “We'll also be taking some of our UK clients with us and enabling them to access the EU market, whether it's giving people access to Bioidentical Hormone Replacement Therapy (BHRT), skin creams or solutions for hair loss to pain management, allergies and intolerances or nutrition. There are a few market dynamics that will be different. While being part of the EU in the same framework, each country has different rules, so we will need to navigate those.”

Once all the regulatory work has been completed, Roseway plans to open its new base in the Netherlands in Spring 2024.

Prescribers can then set up an account and, once verified (following a due diligence process), will be able to access eRoseway, Roseway Labs’ state-of-the-art electronic prescribing system, and submit prescriptions, which will then be dispensed directly to the patient.

“Our market is prescribers with the right attitude who want something that really fits their patients. People who think differently and who want to access something different, to provide a truly personalised service to support their patients’ health and wellness”, adds Elizabeth. “We are excited at the prospect of bringing our services to prescribers in the EU and look forward to building new relationships.”

To find out more, contact:

info@rosewaylabs.com  www.rosewaylabs.com